Head to Head Survey: Swedish Orphan Biovitrum (OTCMKTS:BIOVF) & Williston (OTCMKTS:WHCA)

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) and Williston (OTCMKTS:WHCA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Profitability

This table compares Swedish Orphan Biovitrum and Williston’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Swedish Orphan Biovitrum	-0.97%	13.61%	7.53%
Williston	N/A	N/A	N/A

Valuation and Earnings

This table compares Swedish Orphan Biovitrum and Williston”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Swedish Orphan Biovitrum	$2.46 billion	5.04	$367.52 million	($0.07)	-498.29
Williston	N/A	N/A	N/A	N/A	N/A

Swedish Orphan Biovitrum has higher revenue and earnings than Williston.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Swedish Orphan Biovitrum and Williston, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Swedish Orphan Biovitrum	0	0	1	1	3.50
Williston	0	0	0	0	0.00

Given Williston’s higher possible upside, analysts plainly believe Williston is more favorable than Swedish Orphan Biovitrum.

Summary

Swedish Orphan Biovitrum beats Williston on 6 of the 8 factors compared between the two stocks.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

About Williston

Williston Holding Company, Inc. owns and operates restaurants. The company was incorporated in 2012 and is based in Eden Prairie, Minnesota.